Adjuvant radiotherapy, chemotherapy or surgery alone for high-risk histological node negative esophageal squamous cell carcinoma: Protocol for a multicenter prospective randomized controlled trial
机构:[1]Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China[2]Department of Esophageal Surgery, Tianjin Cancer Hospital, Tianjin Medical University, Tianjin, China[3]Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China[4]Department of Thoracic Surgery, Sichuan Cancer Hospital, Chengdu, China外科中心胸外科中心四川省肿瘤医院胸外科[5]Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China[6]Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China[7]Department of Thoracic Surgery, Fujian Cancer Hospital, Fuzhou, China[8]Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[9]Department of Thoracic Surgery, Hunan Provincial Cancer Hospital, Changsha, China[10]Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao, China[11]Department of Cardiovascular Surgery, Taizhou Hospital affiliated to Wenzhou Medical University, Taizhou, China台州恩泽医疗中心(集团)台州医院[12]Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China[13]Department of Thoracic and Cardiovascular Surgery, Jiangsu Province People’s Hospital and the First Affiliated Hospital of Nanjing Medical University, Nanjing, China江苏省人民医院[14]Department of Thoracic Surgery, Henan Provincial Cancer Hospital, Henan Province, China河南省肿瘤医院
Histologically node negative esophageal squamous cell carcinoma (pN0 ESCC) after radical resection still carries a significant risk of recurrence, especially in high-risk patients. Our previous study showed that the risk of recurrence was associated with tumor location and cell differentiation, as well as the presence of lymphovascular invasion. Most recurrence occurs within two years after surgery. There is still a lack of knowledge on the risks or potential benefits of postoperative adjuvant therapies for high-risk pN0 ESCC patients. This study was designed to evaluate the efficacy and toxicity of adjuvant therapies after radical surgery in high-risk patients with pN0 ESCC. This study is a multicenter, prospective, controlled randomized trial, which will compare the differences between either adjuvant chemotherapy or adjuvant radiotherapy and surgery alone for high-risk pN0 ESCC. Patients in group A will receive three cycles of adjuvant chemotherapy with paclitaxel and cisplatin, patients in group B will receive adjuvant radiotherapy with intensity-modulated radiation of 50 Gy, and patients in group C (the control) will receive surgery alone. The primary endpoint is three-year disease-free survival. Secondary endpoints include toxicity of adjuvant therapies and five-year overall survival. One hundred and sixty-two patients in each group are required and a total of 486 patients will finally be enrolled into the study. This will be the first randomized trial to investigate the necessity or potential benefit of postoperative adjuvant therapies for high-risk pN0 ESCC patients.
第一作者机构:[1]Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
通讯作者:
通讯机构:[1]Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China[*1]Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiaotong University, 241 West Huaihai Road, Shanghai, 200030, China
推荐引用方式(GB/T 7714):
Xufeng Guo,Wentao Fang,Zhigang Li,et al.Adjuvant radiotherapy, chemotherapy or surgery alone for high-risk histological node negative esophageal squamous cell carcinoma: Protocol for a multicenter prospective randomized controlled trial[J].THORACIC CANCER.2018,9(12):1801-1806.doi:10.1111/1759-7714.12882.
APA:
Xufeng Guo,Wentao Fang,Zhigang Li,Zhengtao Yu,Tiehua Rong...&Wenqun Xing.(2018).Adjuvant radiotherapy, chemotherapy or surgery alone for high-risk histological node negative esophageal squamous cell carcinoma: Protocol for a multicenter prospective randomized controlled trial.THORACIC CANCER,9,(12)
MLA:
Xufeng Guo,et al."Adjuvant radiotherapy, chemotherapy or surgery alone for high-risk histological node negative esophageal squamous cell carcinoma: Protocol for a multicenter prospective randomized controlled trial".THORACIC CANCER 9..12(2018):1801-1806